CY1113670T1 - Φαρμακευτικη συνθεση για τη θεραπεια της υπερδραστηριας ουροδοχου κυστης - Google Patents

Φαρμακευτικη συνθεση για τη θεραπεια της υπερδραστηριας ουροδοχου κυστης

Info

Publication number
CY1113670T1
CY1113670T1 CY20131100004T CY131100004T CY1113670T1 CY 1113670 T1 CY1113670 T1 CY 1113670T1 CY 20131100004 T CY20131100004 T CY 20131100004T CY 131100004 T CY131100004 T CY 131100004T CY 1113670 T1 CY1113670 T1 CY 1113670T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
cystus
urinary
treatment
supply
Prior art date
Application number
CY20131100004T
Other languages
English (en)
Inventor
Masanori Suzuki
Masashi Ukai
Akiyoshi Ohtake
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113670(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of CY1113670T1 publication Critical patent/CY1113670T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Σκοπός είναι η παροχήμιας φαρμακευτικής σύνθεσης, η οποία είναι χρήσιμη σαν θεραπευτικός παράγοντας για την υπερδραστήρια ουροδόχο κύστη. Η φαρμακευτική σύνθεση που περιλαμβάνει (R)-2-(2-αμινοθειαζολ-4-υλ)-4'-{2-[(2-υδροξυ-2-φαινυλαιθυλ) αμινο] αιθυλ} ακετανιλίδιο ή ένα φαρμακευτικώς αποδεκτό άλας αυτού και (1S)-1-φαινυλ-1,2,3,4-τετραϋδροϊσοκινολινο-2-καρβοξυλικό (3R)-κινουκλιδιν-3-ύλιο ή ένα φαρμακευτικώς αποδεκτό άλας αυτού, σαν δραστικά συστατικά, και ειδικότερα για τη βελτίωση των συμπτωμάτων που συνοδεύουν την υπερδραστήρια ουροδόχο κύστη, όπως η επείγουσα ούρηση, η συχνουρία ή και η ακράτεια ούρων.
CY20131100004T 2007-11-02 2013-01-04 Φαρμακευτικη συνθεση για τη θεραπεια της υπερδραστηριας ουροδοχου κυστης CY1113670T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007285802 2007-11-02
EP08843784A EP2216021B1 (en) 2007-11-02 2008-10-30 Pharmaceutical composition for treating overactive bladder

Publications (1)

Publication Number Publication Date
CY1113670T1 true CY1113670T1 (el) 2016-06-22

Family

ID=40591069

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100004T CY1113670T1 (el) 2007-11-02 2013-01-04 Φαρμακευτικη συνθεση για τη θεραπεια της υπερδραστηριας ουροδοχου κυστης

Country Status (12)

Country Link
US (2) US20100240697A1 (el)
EP (1) EP2216021B1 (el)
JP (1) JP5263170B2 (el)
CA (1) CA2704298C (el)
CY (1) CY1113670T1 (el)
DK (1) DK2216021T3 (el)
ES (1) ES2393525T3 (el)
HR (1) HRP20121078T1 (el)
PL (1) PL2216021T3 (el)
PT (1) PT2216021E (el)
SI (1) SI2216021T1 (el)
WO (1) WO2009057685A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807135C (en) * 2010-08-03 2019-05-14 Altherx, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US20150306090A1 (en) * 2012-08-31 2015-10-29 Astellas Pharma Inc. Orally administered medical composition
ES2750751T3 (es) * 2014-09-09 2020-03-27 Astellas Pharma Inc Composición farmacéutica novedosa para la prevención y/o el tratamiento de la incontinencia urinaria
KR20170086659A (ko) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
WO2017186598A1 (en) 2016-04-25 2017-11-02 Synthon B.V. Modified release tablet composition comprising mirabegron
EP3448367A1 (en) 2016-04-25 2019-03-06 Synthon BV Tablets comprising mirabegron and solifenacin
US10478399B2 (en) 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron
WO2022006336A1 (en) * 2020-07-01 2022-01-06 Jubilant Pharma Holdings Inc. Long-acting injection dosage form of beta 3 adrenoreceptor agonists
EP4159199A1 (en) 2021-09-29 2023-04-05 Lotus Pharmaceutical Co., Ltd. Combined formulation of mirabegron and solifenacin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
DE69823858T2 (de) 1997-10-17 2005-04-28 Yamanouchi Pharmaceutical Co., Ltd. Amidderivate oder deren salze
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
JP4466370B2 (ja) * 2002-06-07 2010-05-26 アステラス製薬株式会社 過活動膀胱治療剤
DE60336334D1 (de) 2002-11-07 2011-04-21 Astellas Pharma Inc Mittel zur behandlung von blasenhyperaktivität mit einem essigsäureanilid-derivat als wirkstoff
EP1424079A1 (en) 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
ES2290741T3 (es) * 2003-04-04 2008-02-16 Dynogen Pharmaceuticals Inc. Metodo de tratamiento de trastornos del tracto urinario inferior.
EP1682183A2 (de) * 2003-11-03 2006-07-26 Boehringer Ingelheim International Gmbh Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einem alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
EP1726304A4 (en) 2004-03-16 2010-04-28 Astellas Pharma Inc COMPOSITION CONTAINING SOLIFENACIN
US20090131469A1 (en) * 2005-02-25 2009-05-21 Astellas Pharma Inc. Pharmaceutical agent comprising solifenacin
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity

Also Published As

Publication number Publication date
EP2216021A4 (en) 2010-11-03
CA2704298C (en) 2015-07-21
PL2216021T3 (pl) 2013-03-29
JP5263170B2 (ja) 2013-08-14
ES2393525T3 (es) 2012-12-26
US8772315B2 (en) 2014-07-08
JPWO2009057685A1 (ja) 2011-03-10
DK2216021T3 (da) 2012-11-05
HRP20121078T1 (hr) 2013-01-31
CA2704298A1 (en) 2009-05-07
SI2216021T1 (sl) 2013-01-31
PT2216021E (pt) 2012-11-06
EP2216021B1 (en) 2012-10-17
WO2009057685A1 (ja) 2009-05-07
EP2216021A1 (en) 2010-08-11
US20100240697A1 (en) 2010-09-23
US20130150402A1 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
CY1113670T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια της υπερδραστηριας ουροδοχου κυστης
ES2557303T3 (es) Agente terapéutico para la estenosis del canal espinal
RU2015117267A (ru) Замещенные соединения амида
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
CY1114853T1 (el) Μεθοδοι χορηγησης ν-(5-tert-βουτυλ-ισοξαζολυλ-3-υλο)-ν'-{4-[7-(2-μορφολιν-4-υλο-αιθοξυ)ιμιδαζο[2,1-β][1,3]βενζοθειαζολ-2-υλο]φαινυλ]ουριας για αντιμετωπιση υπερπλαστικων νοσων
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
SI1780197T1 (sl) 5-substituirani-2-fenilamino benzamidi kot mek-inhibitorji
EA200900638A1 (ru) СОЛИ И КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 2-МЕТИЛ-2-[4-(3-МЕТИЛ-2-ОКСО-8-ХИНОЛИН-3-ИЛ-2,3-ДИГИДРОИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)ФЕНИЛ]ПРОПИОНИТРИЛА
AR049934A1 (es) Nuevo uso de meloxicam en medicina veterinaria
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
SE0401342D0 (sv) Therapeutic compounds
WO2005051906A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
WO2007126362A8 (en) Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's disease and/or schizophrenia
CL2007001427A1 (es) Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
AR048718A1 (es) Uso de formulaciones de meloxicam en medicina veterinaria
BRPI0518993A2 (pt) composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
TW200606164A (en) New compounds
CL2008001297A1 (es) N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer.
BRPI0816904B8 (pt) Forma cristalna b da forma sólida do sal de bis-hcl, composição farmacêutica, e, uso de uma forma sólida